Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

Dennis C Turk¹, Robert H Dworkin, Laurie B Burke+41

• ¹University of Washington, Seattle, WA 98195, USA University of Rochester School of Medicine and Dentistry, Rochester, NY, USA United States Food and Drug Administration, Rockville, MD, USA Northwestern University, Chicago, IL, USA Johnson and Johnson, Raritan, NY, USA AstraZeneca, Wilmington, DE, USA University of California San Diego, La Jolla, CA, USA Merck and Company, Blue Bell, PA, USA University of Texas, M.D. Anderson Cancer Center, USA American Chronic Pain Association, Rocklin, CA, USA Allergan, Inc, Irvine, CA, USA National Institute of Dental and Craniofacial Research, Bethesda, MD, USA University of Pennsylvania, Philadelphia, PA, USA Johns Hopkins University, Baltimore, MD, USA University Health Network and University of Toronto, Toronto, Canada Novartis Pharmaceuticals, East Hanover, NJ, USA VA Connecticut Healthcare System, West Haven, CT, USA Yale University, New Haven, CT, USA Celgene Corporation, Warren, NJ, USA Pfizer Global Research and Development, Ann Arbor, MI, USA Dalhousie University, Halifax, Nova Scotia, Canada London Regional Cancer Centre, London, Ont., Canada University of Liverpool, Liverpool, UK GlaxoSmithKline, Research Triangle Park, NC, USA Johnson & Johnson, Raritan, NJ, USA Alpharma, Elizabeth, NJ, USA Harvard Medical School, Boston, MA, USA Alpharma, Piscataway, NY, USA University of Munich, Munich, Germany US Department of Veterans Affairs, Washington, DC, USA NeurogesX, Inc, San Carlos, CA, USA Eli Lilly and Co., Indianapolis, IN, USA Endo Pharmaceuticals Inc., Chadds Ford, PA, USA St. Thomas Hospital, London, UK Saint Louis University, St. Louis, MO, USA.